Neostigmine Cooper (Neostigmine Methylsulfate)

The drug reversibly inhibits acetylcholinesterase, the enzyme that breaks down acetylcholine. By blocking this enzyme, acetylcholine levels rise at the neuromuscular junction, enhancing stimulation of nicotinic receptors and counteracting muscle relaxation caused by blocking agents.

Dosing is individualized and must be determined by the prescribing clinician based on the patient’s condition, weight, renal function and the degree of neuromuscular blockade. The product label provides guidance, but the final regimen is set by the healthcare professional.

Safety data for neostigmine methylsulfate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neostigmine is a reversible anticholinesterase, whereas newer agents such as sugammadex bind directly to certain neuromuscular blockers. Neostigmine is less expensive and widely available but may require co‑administration of anticholinergics to manage muscarinic side effects, while sugammadex offers rapid, specific reversal without those effects.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions on the label to maintain product stability.

Neostigmine Cooper is supplied for parenteral use and can be given intravenously, intramuscularly or subcutaneously. The route and rate of administration are determined by the clinician, often as a slow IV injection to reduce the risk of bradycardia and other cholinergic effects.

Serious risks include bradycardia, severe hypotension, bronchospasm, cholinergic crisis leading to muscle weakness or respiratory failure, and rare allergic reactions such as anaphylaxis. Prompt recognition and appropriate management, including the use of anticholinergic agents, are essential.

Neostigmine should be avoided in patients with known hypersensitivity to the drug, severe bradyarrhythmias, uncontrolled asthma or COPD, and in those where the risk of cholinergic excess outweighs the benefit. Contraindications must be confirmed by the prescribing clinician.